Rosetta Genomics last week published data validating its miRview Mets 2 cancer of unknown primary origin diagnostic.
In a paper published in The Oncologist, company researchers reported that the test could use microRNA signatures to identify 42 tumor types with high accuracy, maintaining the performance across patient samples.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
